Seelos Therapeutics Inc (SEEL)
0.92
-0.11
(-10.68%)
USD |
OTCM |
Nov 04, 15:59
Seelos Therapeutics Enterprise Value: 10.27M for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 10.27M |
| October 31, 2024 | 10.26M |
| October 30, 2024 | 10.30M |
| October 29, 2024 | 10.25M |
| October 28, 2024 | 10.37M |
| October 25, 2024 | 10.35M |
| October 24, 2024 | 10.33M |
| October 23, 2024 | 10.32M |
| October 22, 2024 | 10.34M |
| October 21, 2024 | 10.31M |
| October 18, 2024 | 10.26M |
| October 17, 2024 | 10.26M |
| October 16, 2024 | 10.33M |
| October 15, 2024 | 10.37M |
| October 14, 2024 | 10.88M |
| October 11, 2024 | 10.88M |
| October 10, 2024 | 10.89M |
| October 09, 2024 | 11.08M |
| October 08, 2024 | 11.21M |
| October 07, 2024 | 11.17M |
| October 04, 2024 | 11.30M |
| October 03, 2024 | 11.12M |
| October 02, 2024 | 11.24M |
| October 01, 2024 | 11.22M |
| September 30, 2024 | 11.45M |
| Date | Value |
|---|---|
| September 27, 2024 | 11.52M |
| September 26, 2024 | 12.00M |
| September 25, 2024 | 12.18M |
| September 24, 2024 | 11.90M |
| September 23, 2024 | 11.14M |
| September 20, 2024 | 11.21M |
| September 19, 2024 | 11.24M |
| September 18, 2024 | 11.20M |
| September 17, 2024 | 11.39M |
| September 16, 2024 | 11.11M |
| September 13, 2024 | 11.20M |
| September 12, 2024 | 11.14M |
| September 11, 2024 | 11.23M |
| September 10, 2024 | 11.23M |
| September 09, 2024 | 11.28M |
| September 06, 2024 | 11.41M |
| September 05, 2024 | 11.43M |
| September 04, 2024 | 11.51M |
| September 03, 2024 | 11.65M |
| August 30, 2024 | 11.85M |
| August 29, 2024 | 11.83M |
| August 28, 2024 | 11.76M |
| August 27, 2024 | 11.78M |
| August 26, 2024 | 11.96M |
| August 23, 2024 | 12.00M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
4.041M
Minimum
Nov 13 2019
464.37M
Maximum
Apr 28 2021
83.05M
Average
47.95M
Median
Oct 26 2023
Enterprise Value Benchmarks
| 180 Life Sciences Corp | 2.922M |
| Cassava Sciences Inc | 1.050B |
| Cara Therapeutics Inc | -40.33M |
| Citius Pharmaceuticals Inc | 47.55M |
| Moleculin Biotech Inc | -3.876M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.71M |
| Total Expenses (Quarterly) | 3.139M |
| EPS Diluted (Quarterly) | 1.92 |
| Earnings Yield | -51.69K% |